Gene Therapy for Diabetic Retinopathy – Targeting the Renin-Angiotensin System by Li, Qiuhong et al.
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors




the world’s leading publisher of
Open Access books






Gene Therapy for Diabetic Retinopathy – Targeting the
Renin-Angiotensin System
Qiuhong Li, Amrisha Verma, Ping Zhu, Bo Lei,
Yiguo Qiu, Takahiko Nakagawa,
Mohan K Raizada and William W Hauswirth
Additional information is available at the end of the chapter
http://dx.doi.org/10.5772/52702
1. Introduction
1.1. Diabetic retinopathy clinical features and current treatment options
The prevalence of diabetes has been continuously increasing for the last few decades and it
is being recognized as a worldwide epidemic [1]. Diabetic retinopathy (DR) is the most com‐
mon diabetic microvascular complication, and despite recent advances in therapeutics and
management, DR remains the leading cause of severe vision loss in people under age of six‐
ty [2-4]. The prevalence of DR increases with duration of diabetes, and nearly all individuals
with type 1 diabetes and more than 60% of those with type 2 have some form of retinopathy
after 20 years [5-7].
Diabetic retinopathy (DR) is  characterized by the development of progressive pathologi‐
cal changes in the retinal neuro-glial cells and microvasculature. The earlier hallmarks of
diabetic  retinopathy  include  breakdown of  the  blood-retinal  barrier  (BRB),  loss  of  peri‐
cytes, thickening of basement membrane, and the formation of microaneuryms, which are
outpouchings of capillaries [8]. BRB breakdown results in increased vascular permeability
and leakage of fluid into the macula causing macular edema, another significant cause of
vision loss  in  those with diabetes.  With the progression of  diabetic  retinopathy,  hemor‐
rhage,  macular  edema,  cotton  wool  spots,  all  signs  of  retinal  ischemia,  and  hard  exu‐
dates,  the  result  of  precipitation  of  lipoproteins  and  other  circulating  proteins  through
abnormally  leaky  retinal  vessels  become  increasingly  apparent.  More  severe  and  later
stages of diabetic retinopathy, known as proliferative diabetic retinopathy (PDR), is char‐
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acterized by pathological neovascularization. Vision loss can occur from vitreous hemor‐
rhage or from tractional retinal detachment [8, 9].
Despite recent developments in the pharmacotherapy of DR, treatment options for patients
with DR are still limited. Laser photocoagulation, the primary treatment option for patients
with PDR, is still considered gold standard therapy for the treatment of PDR. Although this
treatment slows the loss of vision in those with PDR, it does not represent a cure, and is in
itself a cell destructive therapy. Corticosteroids and anti-VEGF agents have shown promis‐
ing results with regard to prevention of neovascularization, but remain limited in use due to
their short-duration effects. More importantly, none of these agents have been able to substi‐
tute for the durability and effectiveness of laser mediated panretinal photocoagulation in
preventing vision loss in the late stages of DR.
1.2. RAS and diabetic complications
The renin-angiotensin system (RAS) plays a vital role in the cardiovascular homeostasis by
regulating vascular tone, fluid and electrolyte balance, and in the sympathetic nerve system.
Angiotensin II (Ang II), a peptide hormone of RAS, has been known to regulate a variety of
hemodynamic physiological responses, including fluid homeostasis, renal function, and
contraction of vascular smooth muscle [10]. In addition, Ang II is capable of inducing a mul‐
titude of non-hemodynamic effects, such as the induction of reactive oxygen species (ROS),
cytokines, and the stimulation of collagen synthesis [11-14]. Most of the pathophysiological
actions of Ang II are mediated via activation of Ang II type 1 receptors (AT1R), G protein–
coupled receptors (GPCRs) that couple to many signaling molecules, including small G pro‐
teins, phospholipases, mitogen-activated protein (MAP) kinases, phosphatases, tyrosine kin‐
ases, NADPH oxidase, and transcription factors to stimulate vascular smooth muscle cell
growth, inflammation, and fibrosis [11, 15, 16]. Dysregulation of RAS has been implicated in
a number of major cardiovascular and metabolic diseases, including endothelial dysfunc‐
tion, atherosclerosis, hypertension, renal disease, diabetic complications, stroke, myocardial
infarction and congestive heart failure [17, 18]. RAS blockade produces beneficial cardiovas‐
cular and renal effects in numerous clinical trials [19-21].
1.3. Recent advances in RAS research
Recent discoveries have revealed that the RAS hormonal signaling cascade is more com‐
plex than initially conceived with multiple enzymes, effector molecules, and receptors that
coordinately  regulate  the  effects  of  the  RAS.  Recent  studies  have  identified  additional
peptides  with  important  physiological  and  pathological  roles,  new  enzymatic  cascades
that  generate  these  peptides  and  more  receptors  and  signaling  pathways  that  mediate
their function [22, 23].
Discovery of angiotensin-converting enzyme 2 (ACE2) has resulted in the establishment of a
novel axis of the RAS involving ACE2/Ang-(1-7)/Mas [24-27]. ACE2, like ACE, is a zinc-met‐
allopeptidase, exhibiting approximately 42% amino acid identity with ACE in its catalytic
domain. However, unlike somatic ACE, ACE2 only contains a single catalytic site and func‐
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tions as a carboxymonopeptidase, cleaving a single C-terminal residue from peptide sub‐
strates, thus ACE2 is able to cleave Ang II to form Ang (1-7). Ang (1-7), a biologically active
component of the RAS [28-30] binds to a G-protein coupled receptor, Mas receptor [31], and
plays a counter-regulatory role in the RAS by opposing the vascular and proliferative effects
of Ang II [32]. A current view of RAS consists of at least two axis with counteracting biologic
effects (Figure 1).
Figure 1. Schematic diagram depicting the key components of the Renin Angiotensin System. Angiotensinogen is
cleaved by renin to form angiotensin I (Ang I). Angiotensin converting enzyme (ACE) converts Ang I into Angiotensin II
(Ang II) the main effector peptide of the RAS. Ang II elicits is cellular effects by activating the main receptor, Angioten‐
sin II receptor 1 (AT1R), as well as other receptors (not shown). Angiotensin II-converting enzyme 2 (ACE2), a recently
discovered component of RAS, cleaves Ang II to form Angiotensin (1-7) (Ang 1-7), which activate Mas receptor to pro‐
duce counteracting effects mediated by Ang II. All these components are expressed locally in various cell types in the
eye, regulating metabolism, cell survival, and other local neuronal-vascular and immune-modulating functions in the
retina.
This vasoprotective axis of RAS counteracts the traditional proliferative, fibrotic, proinflam‐
matory and hypertrophic effects of the ACE/Ang II/AT1R axis of the RAS [24]. The impor‐
tance of the vasodeleterious axis of the RAS [ACE/angiotensin II (Ang II)/ AT1R] in
cardiovascular disease, as well as in diabetes and diabetic complications, is well established
since ACE inhibitors (ACEi) and angiotensin receptor blockers (ARBs) are leading therapeu‐
tic strategies [20, 33-35]. However, the impact of the vasoprotective axis of the RAS remains
poorly understood [24, 36-38]. The concept that shifting the balance of the RAS towards the
vasodilatory axis by activation of ACE2 or its product, Ang-(1-7) is beneficial has been sup‐
ported by many studies in cardiac, pulmonary, and vascular fibrosis [24, 39-43]. Indeed,
ACE2/Ang-(1-7) activation is now considered to be a critical part of the beneficial actions of
ACEi and ARB drugs [24, 36].
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1.4. Tissue RAS in end-organ damage
The classical (endocrine) RAS has been traditionally regarded as systemic hormonal sys‐
tem. Ang II  is  formed from liver-synthesized angiotensinogen via a series of  proteolytic
cleavage events.  Circulating Ang II  activates  AT1 and AT2 receptors  in  various tissues,
such  as  the  brain,  adrenal  and  vascular  tissues  to  modulate  cardiovascular  and  hydro‐
mineral homeostasis.
However, most components of RAS have also been identified in essentially every organ in‐
cluding kidney, heart, liver, brain, adipose tissue, reproductive tissue, hematopoietic tissue,
immune cells and eye, and increasing evidence supports the existence of tissue- specific RAS
that exerts diverse physiological effects locally and independently of circulating Ang II
[44-46]. These tissue- specific paracrine, intracrine andautocrine actions of RAS may contrib‐
ute to end-organ damage in many pathological conditions including diabetic complications
and maybe the basis for the reported limited beneficial effects of RAS blockade.
2. Ocular RAS in pathogenesis of diabetic retinopathy
Increasing evidence continues to implicate the involvement of the local renin-angiotensin-
system (RAS) in retinal vascular dysfunctions. Various components of RAS have been de‐
tected in the different cell types of the eye (Table 1).
RAS components Retinal Localization Reference
Angiotensinogen Retinal microvasculature, RGCs, RPE [47, 48]
Angiotensin I Aqueous, vitreous, and subretinal fluid [49]
Angiotensin II Aqueous, vitreous, and subretinal fluid, RGCs, retinal endothelial cells and
photoreceptors
[49-51]
Angiotensin 1-7 Muller cells [50]
Renin Muller cells and vitreous fluid [52, 53]
Renin receptor Retinal microvasculature, microglia, astrocytes, RGCs, RPE [54-58]
ACE Muller cells, RGCs, retinal endothelial cells, photoreceptors, and vitreous [51, 59-61]
ACE2 Retina [50]
AT1R Muller cells, retinal blood vessels, photoreceptors and RGCs [50, 51]
AT2R Muller cells, nuclei of some inner, nuclear layer neurons, and ganglion cells [50]
Mas receptor RGCs, retinal microvasculature, microglia, subset of astrocytes unpublished results
GC: retinal ganglion cells; RPE: retinal pigment epithelium.
Table 1. All components of RAS are expressed locally in the eye.
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Hyperglycemia has been shown to directly stimulate angiotensin gene expression via the hex‐
ominase pathway, thus contributing to increased Ang II synthesis [62]. Elevated levels of re‐
nin, prorenin, and Ang II have been found in patients with DR. In fact, ACE inhibitors and
angiotensin receptor blockers (ARBs) have been shown to improve diabetes-induced vascular,
neuronal, and glial dysfunction [61, 63-66]. Recent clinical studies have also clearly demon‐
strated the beneficial effects of RAS inhibition in both type 1 and type 2 diabetic patients with
retinopathy [67-71]. Despite these positive outcomes, RAS blockers are not completely retino‐
protective and retinopathy still progresses to more advanced stages. This could be attributed
to the existence of local Ang II formation and that current therapeutic agents are unable to cross
the blood-retina barrier (BRB) in a concentration sufficient to influence the local RAS in the eye.
In addition, increasing evidence suggests that Ang II can be generated via multiple pathways,
many of which may not be blocked by classic inhibitors of ACE [72-75]. Furthermore, addition‐
al components of RAS that contribute to end-organ damage, such as receptors for renin and
prorenin (PRR), have been recently identified [76]. Activation of prorenin/PRR signaling path‐
way can initiate the RAS cascade independent of Ang II [76].
Ang II may contribute to development and progression of DR by several mechanisms. First,
Ang II has been shown to increase VEGF expression directly via activation of AT1R signaling
and indirectly by PCK activation [77] to enhance the role of VEGF induced vascular permeabil‐
ity and angiogenesis. Treatment with ACE inhibitors reduces vitreous levels of VEGF and at‐
tenuates VEGF-mediated BRB breakdown [78, 79]. Second, Ang II, mediated via AT1R, also
contributes to diabetes-induced retinal inflammation by activation of nuclear factor-κβ signal‐
ing pathway within retinal endothelial cells [80, 81] leading to the release of inflammatory cy‐
tokines which perpetuates the inflammatory cycle. Pro-inflammatory cytokines, chemokines
and other inflammatory mediators play an important role in the pathogenesis of DR [82, 83].
These lead to persistent low-grade inflammation, the adhesion of leukocytes to the retinal vas‐
culature (leukostasis), breakdown of BRB and neovascularization with subsequent sub-retinal
fibrosis or disciform scarring [84-88]. Third, Ang II may contribute to increased oxidative stress
in diabetic retina. Ang II induces reactive oxygen species (ROS) production by activation of
NADPH oxidases [89], which has been implicated in diabetic complications [90, 91]. Ang II al‐
so induces mitochondrial ROS production, which further stimulate of NADPH oxidases lead‐
ing to vicious cycle and contributing tissue damage [92, 93].
Fourth, Ang II may also contribute to neuronal dysfunction induced by diabetes [94]. Recep‐
tors for Ang II are also expressed in the inner retinal neurons (Table 1). Ang II induced
AT1R signaling may cause neuronal dysfunction by reducing the synaptophysin protein in
the synaptic vesicles [94].
3. Protective role of the ACE2/Ang1-7-Mas axis of RAS in diabetic
complications
The discovery of ACE2- mediated degradation of Ang II into the protective peptide Ang 1-7
thereby negatively regulating the classic RAS, has instigated stimulated interest regarding
the potential of ACE2 as a therapeutic target [88, 89], and strategies aimed at enhancing
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ACE2 action may have important therapeutic potential for cardiovascular disorders as well
as for diabetic complications [40, 95-99]. Ang (1-7) has been shown to prevent diabetes-in‐
duced cardiovascular dysfunction [100] and nephropathy [101]. The protective effect of Ang
1-7 signaling is at least in part mediated by direct inhibition of diabetes-induced ROS pro‐
duction due to elevated NADPH oxidase activity [101, 102] and reduction in PPAR-gamma
and catalase activities [102]. Adenovirus mediated gene delivery of human ACE2 in pan‐
creas improved fasting blood glucose, beta-cell dysfunction and apoptosis occurring in type
2 diabetes mouse model [103]. The importance of ACE2 as a negative regulator of RAS in
diabetic complications is supported by the facts that ACE2 deficiency exacerbates diabetic
complications [104, 105] and enhancing ACE2 action counteracts the deleterious effects of
Ang II and produces protective effects [96-99, 106].
3.1. Diabetes induced changes in the expression of the retinal RAS genes in the mouse
retina during the progression of diabetes
We have previously shown that diabetes induced by STZ treatment in eNOS-/- mice results
in more severe, accelerated retinopathy than diabetes in untreated eNOS+/+ animals [107].
Thus it became critical to compare retinal mRNA levels of the RAS genes in control and dia‐
betic animals during the progression of diabetes. We observed significant (3-10 fold) increas‐
es in the mRNA levels of the vasodeleterious axis of the RAS (angiotensinogen, renin, pro/
renin receptor, ACE and AT1 receptor subtypes) following STZ treatment (Figure 2) [108]. In
contrast, there was ~ 30% reduction in ACE2 mRNA following an initial stimulatory re‐
sponse. As a result the ACE/ACE2 mRNA ratio was increased by 10-fold, while AT1R/Mas
ratio was increased by 3-fold following one month of diabetes (Figure 2). These observations
were our initial indication that DR is associated with a shifting balance of the retinal RAS
towards vasodeleterious axis.
3.2. Enhancing ACE2/Ang1-7-Mas axis by AAV-mediated gene delivery
3.2.1. Characterization of AAV vectors expressing ACE2 and Ang-(1-7)
AAV vector expressing the secreted form of human ACE2 was constructed under the control of
the chicken-beta-actin (CBA) promoter (Figure 3A). This secreted form of ACE2 has been pre‐
viously characterized and shown to be active enzymatically [109]. Since Ang-(1-7) peptide con‐
tains only 7 amino acids and small peptides are usually difficult to express in mammalian cells,
we designed an expression construct in which the Ang-(1-7) peptide is expressed as part of the
secreted fusion GFP protein, and is subsequently cleaved upon secretion into the active pep‐
tide. Expression of the fusion sGFP-FC-Ang-(1-7) is under the control of the CBA promoter in
the AAV vector (Figure 3A) and was confirmed by tranfecting HEK293 cells using this plas‐
mid DNA (Figure 3B). To ensure that the fusion protein was indeed secreted, proteins isolated
from the culture supernatants as well as cell lysates from transfected, sham-transfected or un‐
transfected cells were analysized by western blotting (Figure 3B). Mass spectrometry analysis
of Ang (1-7) peptide in supernatant samples of HEK293 cells transfected with the sGFP-FC-
Ang-(1-7) plasmid DNA was also performed. The Ang-(1-7) peptide is detectable in superna‐
tant isolated from cells transfected with sGFP-FC-Ang-(1-7) plasmid DNA, but not detectable
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in samples isolated from un-transfected cells, or cells transfected with the control plasmid ex‐
pressing only the cytoplasmic GFP protein (data not shown). Intravitreal administration of
AAV-Ang-(1-7) resulted in a robust transduction of retinal cells primarily within the inner reti‐
nal layer (Figure 3C-F). This was associated with an increase in both cellular and secreted Ang-
(1-7)  (Figure 3G-H).  Similarly,  ACE2 protein level  was increased in the retina following
transduction with AAV-ACE2 (Figure 3G).
Figure 2. Real-time RT-PCR analysis of retinal mRNA for renin-angiotensin system genes. Values represent fold differ‐
ence compared to age matched non-diabetic retinal samples for each gene at each time point (14 day and 1 month
after induced diabetes). DM: diabetic. NDM: non-diabetic. At least 4 eyes were analyzed at each time point. *p<0.01
(versus NDM group). (From [108] with permission of Mol. Therapy).
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Figure 3. Construction and characterization of AAV vectors expressing ACE2 and Ang-(1-7).A: Maps of the AAV vector
expressing the human ACE2 gene (hACE2) and the AAV vector expressing Ang-(1-7) gene. The Ang-(1-7) peptide is
expressed as part of fusion protein, and cleaved in vivo upon secretion at the furin cleavage (FC) site. ITR: inverted
terminal repeat; CBA: CMV- chicken-β-actin promoter. A control vector contains the coding region for the secreted
GFP without the Ang-(1-7) peptide coding sequence. B: Expression and cleavage of the fusion protein. In cultured
HEK293 cells transfected with the plasmid sGFP-FC-Ang-(1-7), or infected with AAV-sGFP-FC-Ang-(1-7), there was ro‐
bust expression of GFP as expected. Proteins isolated from cell lysates contained a single protein band with molecular
weight ~30 kd, as predicted for the precursor (fusion protein), but culture supernatants contained two protein bands
(30kd and a 27kd), indicating that the secreted protein is cleaved at the furin cleavage site as predicted. C-F: Transduc‐
tion of mouse retina with AAV vector expressing sGFP-FC-Ang-(1-7) and hACE2. A single intravitreal injection of 1μl
AAV vector (109 vg/eye) resulted in efficient transduction of inner retinal cells, primarily retinal ganglion cells. C. Low
magnification of cross section of a mouse eye that received AAV2-sGFP-FC-Ang-(1-7) injection. D. Higher magnifica‐
tion of the same eye. E. A retinal whole mount showing GFP expression. F. Higher magnification of the same retinal
whole mount. G: Western blot of proteins isolated from an uninjected eye and an eye injected with AAV2-ACE2 (top)
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and AAV2-sGFP-FC-Ang-(1-7) (bottom) compared to a molecular weight standard (right lane). H: Ang-(1-7) peptide
levels in the retina with and without AAV-sGFP-FC-Ang-(1-7) injection. There was more than a 10-fold increase in Ang-
(1-7) peptide level detected by using an Ang-(1-7) specific EIA kit (Bachem, San Carlos, CA) in retinas receiving injec‐
tion of AAV-sGFP-FC Ang-(1-7). PR: photoreceptor; OPL: outer plexiform layer; INL: inner nuclear layer; IPL: inner
plexiform layer; RGC: retinal ganglion cells. (From [108] with permission of Mol. Therapy).
3.2.2. Ocular gene delivery of ACE2/Ang-(1-7) via the AAV vector in the retina results increased
ACE2 activities and Ang-(1-7) peptide levels
Diabetes induced more than a 5-fold increase in ACE activity in the retinas of eNOS-/- mice,
whereas ACE2 activity was relatively unchanged (Figure 4A). AAV2-ACE2 injected retinas
show more than a two-fold increase in ACE2 enzymatic activity (Figure 4A) and this is asso‐
ciated with a reduced level of Ang II and increased Ang-(1-7) peptide level (Figure 4B), but
has only a marginal effect on ACE activity (Figure 4A). Injection of AAV2-Ang-(1-7) has no
effect on ACE2 activity, but significantly decreased ACE activity (Figure 4A).
We also determined Ang II and Ang-(1-7) peptide levels using a commercial EIA kit (Bach‐
em, San Carlos, CA). STZ induced diabetes resulted in more than a 2-fold increase in Ang II
levels whereas the Ang-(1-7) level was unchanged in the retinas of eNOS-/- mice (Figure 4B).
This increase of Ang II was completely normalized in retinas injected with AAV-ACE2 but
was unchanged in retinas injected with AAV-Ang-(1-7) vector (Figure 4B).
Figure 4. ACE, ACE2 activities and angiotensin peptide levels in the mouse retina.A: ACE and ACE2 enzymatic activities
and ACE/ACE2 ratios in non-diabetic (NDM), 1 month diabetic (1M DM), and 1 month diabeticeNOS-/- mouse retinas
treated with AAV-ACE2/Ang-(1-7). Values are expressed as fold differences compared with age-matched non-diabetic
group. *p<0.01 (versus untreated DM group, N=6/group). B: Ang II and Ang-(1-7) peptide levels in non-diabetic
(NDM), 1 month diabetic (1M DM), and 1 month diabetic eNOS-/- retinas treated with AAV-ACE2/Ang-(1-7), meas‐
ured by ELISA using a commercial kit. *p<0.01 (versus untreated DM group). Values represent fold difference com‐
pared with age-matched non-diabetic group. Three retinas were pooled for each measurement, each measurement
was done in duplicates, and three separate pools were averaged for each group. (From [108] with permission of Mol.
Therapy).
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3.3. Protective role of ACE2/Ang (1-7) AAV gene delivery in mouse model of DR
3.3.1. Enhanced ACE2/Ang1-7 expression in the retina reduced diabetes-induced retinal vascular
leakage
We investigated if elevated expression of retinal ACE2 or Ang-(1-7) would overcome the
vasodeleterious effect of the ACE/AT1R axis and prevent the development of diabetes-in‐
duced retinopathy. Effects of increased ACE2 and Ang-(1-7) expression on retinal vascular
permeability were evaluated by FITC-labeled albumin extravasations and quantified by
measuring its fluorescence intensity in serial sections from non-diabetic, untreated, ACE2
treated diabetic eNOS-/- mice and Ang 1-7 treated diabetic eNOS-/- mice. Induction of diabe‐
tes for 2 month in eNOS-/- mice resulted in a 2-fold increase in vascular permeability. This
pathophysiology was significantly reduced in diabetic retinas which received ACE2/Ang-
(1-7) vector treatments (Figure 5), but not in the retinas receiving control vector containing
the coding sequence for secreted GFP without Ang-(1-7) or ACE2 (data not shown).
Figure 5. Effects of ocular treatments with ACE2 and Ang-(1-7)-AAV2 on retinal vascular permeability in diabetic
eNOS-/- mice. Retinal vascular permeability was evaluated by FITC-labeled albumin extravasations and quantified by
measuring the fluorescence intensity in serial sections from eNOS-/- mice at 1 month after induced diabetes. Data are
presented as mean ± SD from 6 eyes in each group. *p<0.01 (versus untreated DM group). NDM: non-diabetes; DM:
diabetes. (From [108] with permission of Mol. Therapy).
3.3.2. Increased expression of ACE2 and Ang1-7 resulted in reduced ocular inflammation in diabetic
retina
Diabetes-induced ocular inflammation, as demonstrated by increased infiltrating CD45 posi‐
tive macrophages and activation of CD11b positive microglial cells, was significantly re‐
duced in eyes treated with ACE2 and Ang-(1-7) expression vectors (Figure 6).
3.3.3. Increased ACE2/Ang1-7 expression reduced the number of acellular capillaries in the diabetic
retina
Induction of diabetes for 2 month in eNOS-/- mice resulted in a >10-fold increase in the for‐
mation of acellular capillaries that was significantly reduced in diabetic retinas which re‐
ceived ACE2/Ang-(1-7) vector treatments (Figure 7). Furthermore, increasing the level of
ACE2 also prevented basement membrane thickening in diabetic eNOS-/- retina (Figure 8).
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Figure 6. Intravitreal administration of ACE2 or Ang-(1-7)-AAV reduces diabetes-induced ocular inflammation. A. Quan‐
tification of CD45positive inflammatory cells in the retinas from untreated non-diabetic, ACE2 treated and Ang-(1-7)
treated diabetic eNOS-/- mouse retinas at 1 month after induced diabetes or the equivalent age in untreated controls. B.
Quantification of CD11b positive inflammatory cells in the retinas from untreated non-diabetic, ACE2 treated and Ang-
(1-7) treated diabetic eNOS-/- mouse retinas at 1 month after induced diabetes or the equivalent age in untreated con‐
trols. N=4 for each group. *p<0.01 (versus untreated DM group). (From [108] with permission of Mol. Therapy).
Figure 7. Evaluation of acellular capillary formation in untreated and AAV-ACE2/Ang-(1-7) treated retinas of diabetic
mice. Treatments with ACE2 and Ang 1-7 vectors in the diabetic eNOS-/- mouse retinas reduced acellular capillaries.
A: Representative images of trypsin-digested retinal vascular preparations from untreated non-diabetic eNOS-/-, ACE2
and Ang-(1-7) treated diabetic eNOS-/- mouse retinas (2 months after induced diabetes or the equivalent age in un‐
treated controls. Arrows indicate the acellular capillaries. B. Quantitative measurements of acellular capillaries. The val‐
ues on Y-axis represent the number of acellular capillaries per mm2 retina. NDM: non-diabetes; DM: diabetes. N=6.
*p<0.01 (versus untreated DM group). (From [108] with permission of Mol. Therapy).
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Figure 8. Transmission electron micrographs of retinal capillaries from a untreated 2 month diabetic eNOS-/- mouse
eye (A), and an eye that received AAV-ACE2 treatment 2 weeks before STZ-induction of diabetes (B). CL: capillary lu‐
men; En: endothelial cell; P: pericyte; * indicates the capillary basement membrane. Scale bar = 500nm. We have previ‐
ously shown that the basement membranes of retinal capillaries from the diabetic eNOS-/- animals at two months
after STZ induction of diabetes was significantly thicker than those from age-matched, non-diabetic animals [107].
The thickening of the basement membrane was prevented in the AAV-ACE2 treated eyes (73.81+17nm, versus
95.72+20 nm in untreated DM eye).
3.4. Protective role of ACE2/Ang (1-7) AAV gene delivery in a rat model of DR
3.4.1. Increased ACE2/Ang1-7 expression reduced the number of acellular capillaries in the diabetic
rat retina
We also used STZ-induced diabetic SD rats as an additional animal model of diabetes to
provide conceptual validation. We observed more than a 5-fold increase in the number of
acellular capillaries in STZ-induced diabetic rat retinas at 14 month of diabetes. This increase
was almost completely prevented by gene delivery of either ACE2 or Ang-(1-7) (Figure 9).
3.4.2. Increased expression of ACE2/Ang-(1-7) reduces oxidative damage in diabetic retina
Diabetes and its complications are associated with increased oxidative stress. We assessed
oxidative damage measuring the levels of thiobarbituric acid-reactive substances (TBARs, is
a marker for oxidative damage [110]) in the retina). Diabetes induced a significant increase
in TBARs (Figure 10A) in eNOS-/- mouse retinas (Figure 10A). This increase is completely
prevented by AAV-ACE2 or Ang-(1-7) treatment. Similar results were also obtained in SD
rat retinas (Figure 10B).
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Figure 9. Evaluation of acellular capillary formation in untreated and ACE2/Ang-(1-7) AAV2 vector treated retinas of
diabetic SD rats. (A) Representative images of trypsin-digested retinal vascular preparations from non-diabetic SD rat,
untreated, ACE2 and Ang-(1-7) treated diabetic SD rat retinas (14 months after induced diabetes). (B) Quantitative
measurements of acellular capillaries. Values on Y-axis represent the number of acellular capillaries per mm2of retina.
NDM: non-diabetes; DM: diabetes. N=6. *p<0.01(versus untreated DM group). (From [108] with permission of Mol.
Therapy).
Figure 10. TBARs levels in eNOS-/- mouse retinas (A) and SD rat retinas (B). Diabetes resulted in increased TBARs levels
in both eNOS-/- mouse retinas at1 month of diabetes and SD rat retinas at 4 months of diabetes. These increases were
prevented by AAV-ACE2/Ang-(1-7) treatments. NDM: non-diabetes; DM: diabetes. N=6/group. *p<0.01(vs untreated
DM). (From [108] with permission of Mol. Therapy).
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3.5. Possible mechanisms of protective action of ACE2/Ang (1-7) in diabetic retina
We demonstrate that all the genes within the RAS are expressed in the retina, consistent
with various previous reports (reviewed in [111] and references therein), and the expression
levels of genes in the vasoconstrictive arm of RAS (renin, ACE, AT1R) are highly elevated in
diabetic retinas, whereas there is initial increase in the expression of genes in the vascodila‐
tive axis (ACE2 and MAS) earlier in diabetes that attenuate over time with the progression
of diabetes, thus tipping the balance towards more vasoconstrictive, proinflammatory, hy‐
pertrophic effects of RAS mediated by ACE/Ang II/AT1R axis. This is associated with in‐
creased ACE activity and Ang II levels in diabetic retinas, whereas ACE2 activity and Ang-
(1-7) levels are not significantly changed, while the mRNA levels for ACE2 and Mas
receptor are reduced under these conditions.
Furthermore, we show that enhanced expression of either ACE2 or Ang-(1-7) via AAV vec‐
tor mediated gene delivery in the retina prevents diabetes-induced retinal vascular permea‐
bility, thickening of basement membrane, retinal inflammation, formation of acellular
capillaries, and oxidative damage in both mouse and rat models of diabetic retinopathy.
More importantly, these beneficial effects occur in the absence of systemic control of glu‐
cose, blood pressure, which is elevated in eNOS-/- mice [107], and other diabetic complica‐
tions [112], suggesting that local RAS activation plays a significant role of pathogenesis of
diabetic retinopathy, and can be modulated locally to restore the balance between the two
counter-acting arms by enhancing the ACE2/Ang-(1-7)/MAS axis. These observations pro‐
vide conceptual support that enhancing ACE2/ Ang-(1-7) axis maybe an effective strategy
for the treatment of DR.
Although various components of RAS have been detected in retina, our study is the first to
examine the expression levels of all known RAS genes during the progression of diabetes in
the eNOS-/- mice, which exhibit accelerated retinopathy [107]. We show that increased ex‐
pression of genes in the vasoconstrictive, proinflammatory axis of RAS (ACE, AT1R, renin,
renin receptor) occur early, 14 days after STZ-induced diabetes. We have previously shown
that increased retinal vascular permeability and gliosis are already detectable at this time
point in diabetic eNOS-/- mouse retina, suggesting that local hyperactivity of the deleterious
axis (ACE/Ang II/AT1R) may contribute to these pathological changes. We also measured
ACE and ACE2 activities in diabetic eNOS-/- mouse retina. In contrast to a previous report
which showed that ACE enzyme activity was decreased, whereas ACE2 enzyme activity
was increased in diabetic rat retinas [113], we found that ACE activity is highly increased in
diabetic retinas, whereas ACE2 activity remains unchanged. This discrepancy may be due to
the difference in animal models or the time points at which these assays were performed.
The importance of the vasodeleterious axis of the RAS (ACE/ Ang II/ AT1R) in cardiovascu‐
lar disease, as well as in diabetes and diabetic complications, is well established since ACE
inhibitors (ACEi) and angiotensin receptor blockers (ARBs) are leading therapeutic strat‐
egies [20, 33-35]. However, the impact of the vasoprotective axis of the RAS remains poorly
understood, particularly in the eye. The concept that shifting the balance of the RAS towards
the vasodilatory axis by activation of ACE2 or its product, Ang-(1-7) is beneficial has been
supported by many studies in cardiac, pulmonary, and vascular fibrosis [24, 36-38]. We
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show that increased expression of either ACE2 or Ang-(1-7) is protective in both eNOS-/-
mouse and rat models of diabetic retinopathy. However the action of ACE2 and Ang-(1-7)
may be different. The protective effect of ACE2 may result from reduced Ang II, by catalyz‐
ing its conversion to Ang-(1-7), thus increasing the level of Ang-(1-7), or combination of
both. Indeed, in the AAV-ACE2 treated retina diabetes-induced elevation of Ang II is re‐
duced and this is associated with an increased level of Ang-(1-7). On other hand, the fact
that increased Ang-(1-7) expressed from AAV vector in the retina is also protective and that
the Ang II level remained high in AAV-Ang-(1-7) treated retinas suggest that Ang-(1-7) can
produce physiological responses that direct counteract these of Ang II, consistent with well-
established effects of Ang-(1-7) [114].
It is interesting to note that ACE2 over-expression resulted in reduced Ang II and increased
Ang-(1-7) levels as expected, but has no effect on ACE activity. However, over-expression of
Ang-(1-7) had no effect on endogenous ACE2 activity, but significantly reduced ACE activi‐
ty. Paradoxically, despite reduced ACE activity in AAV-Ang-(1-7) treated retinas, Ang II
levels remained high. It is possible that other enzymes/pathways may be involved in Ang II
formation in addition to ACE. One such candidate is chymase, which has been detected in
vascular systems and other tissues including eye [115]. Another candidate is the receptor for
prorenin and renin (pro/renin). It has been recently demonstrated that binding of pro/renin
to its receptor, pro/renin receptor (PRR), causes its prosegment to unfold, thereby activating
prorenin so that it is able to generate angiotensin peptides that stimulate the Ang II-depend‐
ent pathway [76]. Considering the fact that retina contains high level of prorenin, and its lev‐
el is further increased in patients with diabetic retinopathy [52], this pathway likely
contributes to increased Ang II level under diabetic conditions. The existence of multiple
pathways for Ang II formation at the tissue level may explain the limited beneficial effects of
classic RAS blockers, and may also lend support for thtoe notion that enhancing the protec‐
tive axis of RAS (ACE2/Ang-(1-7)/Mas) may represent a more effective strategy for treat‐
ment of diabetic retinopathy and other diabetic complications.
AAV vector mediated gene therapy for ocular diseases has been studied in animal models
for more than a decade. Reports focusing on retinal therapy include a wide variety of retinal
degenerative animal models of corresponding human retinopathies, as well as the therapeu‐
tic effects of AAV-vector mediated expression of neuroprotective, anti-apoptotic, and anti-
angiogenic agents in the retina [116]. In view of recent clinical trials in which AAV delivered
RPE65 gene led to restoration of vision in human patients and other reports on successful
trials on treatment of ocular diseases and inherited immune deficiencies (reviewed in [117]
and references therein), gene therapy has emerged as promising approach and may become
a standard treatment option for a wide range of diseases in the future. In particular, when
considering that the diabetic individual experience this serious ocular complication for deca‐
des, a therapeutic strategy that is long-lasting and does not require patient compliance is
particularly desirable. Thus, the delivery of ACE2 and/or Ang-(1-7) could serve as a novel
gene therapeutic target for DR in combination with existing strategies to control hyperglyce‐
mic and insulin resistance states.




All genes of the RAS are locally expressed in the retina, establishing the existence of an in‐
trinsic retinal RAS. It is clear that the expression of genes of the vasoconstrictive/pro-inflam‐
matory/ proliferative/fibrotic (i.e., vasodeleterious) axis (ACE/Ang II/AT1R) is highly
elevated, while the vasoprotective axis [ACE2/Ang-(1-7)/Mas] is decreased in the diabetic
retina. We have demonstrated that increased expression of ACE2 or Ang-(1-7), two key
members of the vasoprotective axis, via AAV-mediated gene delivery to the retina attenu‐
ates diabetes-induced retinal vascular pathology. Moreover, these beneficial effects of gene
transfer occur without influencing the systemic hyperglycemic status. Thus, strategies en‐
hancing the protective ACE2/Ang-(1-7) axis of RAS could serve as a novel therapeutic target
for DR.
5. Implications and future challenges
Hyperactivity of RAS, resulting in elevated concentrations of the principal effector peptide
Ang II, is central to pathways leading to increased vascular inflammation, oxidative stress,
endothelial dysfunction and tissue remodeling in variety of conditions including heart fail‐
ure, stroke, renal failure, diabetes and its associated complications including DR. As a result,
RAS inhibitors are one of the first-line therapeutic agents for treating patients with cardio‐
vascular diseases, metabolic syndrome, diabetes and diabetic complications. Ang II block‐
ade has shown to be antiangiogenic [66, 118, 119], anti-inflammatory [120] and improves
retinal function [65], and indeed Ang II blockade therapy for retinopathy is in several clini‐
cal trials [67, 68, 121]. Despite the clear beneficial effects of RAS blockers (ACE inhibitors
[ACEi] and angiotensin receptor blockers [ARBs]) [70, 71, 122], end-organ damage still en‐
sue in patients with diabetes. Overwhelming evidence now supports the notion thatactiva‐
tion of RAS at tissue levels contributes to the development and progression of diabetic
complications including DR, independent of circulating RAS regulation. However the pre‐
cise molecular and cellular mechanisms as to how retinal RAS contributes to the develop‐
ment and progression of DR remain to be elucidated. Recent studies have also revealed the
evolving complexity of RAS with a myriad cellular and intracellular pathways leading to
formation of Ang II, as well as Ang II- independent signaling pathways resulting in hyper‐
activity of tissue RAS. The physiological implications of many of these components are still
not well understood and new antagonists/agonists specific to these new components remain
to be discovered. Nevertheless, our results clearly demonstrate that enhancing the protective
axis of RAS (ACE2/Ang1-7/Mas) locally may be a better strategy for counteracting the effects
of the pathological RAS activation than present systemic approaches. Furthermore, since
AAV vector mediated gene delivery has been shown to be safe, and improve vision for ex‐
tended periods of time after a single administration in several clinical trials, enhancing the
endogenous protective axis of RAS (ACE2/Ang1-7/Mas) by local gene delivery, in combina‐
tion with combination with existing strategies to control hyperglycemic and insulin resist‐
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ance states may represent a better strategy for preventing and treating diabetic
complications such as diabetic retinopathy.
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